Literature DB >> 30640548

Trials and Tribulations in Studying Kidney Outcomes With Intentional Weight Loss.

Sankar D Navaneethan1,2.   

Abstract

Entities:  

Keywords:  Editorials; kidney diseases; obesity; weight loss

Mesh：

Substances：

Year:  2019        PMID： 30640548      PMCID： PMC6336107          DOI： 10.1161/CIRCULATIONAHA.118.038677

Source DB:  PubMed          Journal:  Circulation        ISSN： 0009-7322            Impact factor:   29.690


× No keyword cloud information.
  15 in total

1.  Multicenter, placebo-controlled trial of lorcaserin for weight management.

Authors:  Steven R Smith; Neil J Weissman; Christen M Anderson; Matilde Sanchez; Emil Chuang; Scott Stubbe; Harold Bays; William R Shanahan
Journal:  N Engl J Med       Date:  2010-07-15       Impact factor: 91.245

2.  Orlistat and acute kidney injury: an analysis of 953 patients.

Authors:  Matthew A Weir; Michael M Beyea; Tara Gomes; David N Juurlink; Muhammad Mamdani; Peter G Blake; Ron Wald; Amit X Garg
Journal:  Arch Intern Med       Date:  2011-04-11

3.  Lorcaserin and Renal Outcomes in Obese and Overweight Patients in the CAMELLIA-TIMI 61 Trial.

Authors:  Benjamin M Scirica; Erin A Bohula; Jamie P Dwyer; Arman Qamar; Silvio E Inzucchi; Darren K McGuire; Anthony C Keech; Steven R Smith; Sabina A Murphy; Kyungah Im; Lawrence A Leiter; Milan Gupta; Tushar Patel; Wenfeng Miao; Carlos Perdomo; Marc P Bonaca; Christian T Ruff; Marc S Sabatine; Stephen D Wiviott
Journal:  Circulation       Date:  2019-01-15       Impact factor: 29.690

Review 4.  Interpreting different measures of glomerular filtration rate in obesity and weight loss: pitfalls for the clinician.

Authors:  D R Jesudason; P Clifton
Journal:  Int J Obes (Lond)       Date:  2011-12-20       Impact factor: 5.095

Review 5.  Kidney Function in Obesity-Challenges in Indexing and Estimation.

Authors:  Alex R Chang; Waleed Zafar; Morgan E Grams
Journal:  Adv Chronic Kidney Dis       Date:  2018-01       Impact factor: 3.620

6.  Body mass index and risk for end-stage renal disease.

Authors:  Chi-yuan Hsu; Charles E McCulloch; Carlos Iribarren; Jeanne Darbinian; Alan S Go
Journal:  Ann Intern Med       Date:  2006-01-03       Impact factor: 25.391

7.  Cardiovascular Safety of Lorcaserin in Overweight or Obese Patients.

Authors:  Erin A Bohula; Stephen D Wiviott; Darren K McGuire; Silvio E Inzucchi; Julia Kuder; KyungAh Im; Christina L Fanola; Arman Qamar; Conville Brown; Andrzej Budaj; Armando Garcia-Castillo; Milan Gupta; Lawrence A Leiter; Neil J Weissman; Harvey D White; Tushar Patel; Bruce Francis; Wenfeng Miao; Carlos Perdomo; Shobha Dhadda; Marc P Bonaca; Christian T Ruff; Anthony C Keech; Steven R Smith; Marc S Sabatine; Benjamin M Scirica
Journal:  N Engl J Med       Date:  2018-08-26       Impact factor: 91.245

8.  Liraglutide and Renal Outcomes in Type 2 Diabetes.

Authors:  Johannes F E Mann; David D Ørsted; Kirstine Brown-Frandsen; Steven P Marso; Neil R Poulter; Søren Rasmussen; Karen Tornøe; Bernard Zinman; John B Buse
Journal:  N Engl J Med       Date:  2017-08-31       Impact factor: 91.245

9.  Overweight, obesity and intentional weight loss in chronic kidney disease: NHANES 1999-2006.

Authors:  S D Navaneethan; J P Kirwan; S Arrigain; M J Schreiber; A R Sehgal; J D Schold
Journal:  Int J Obes (Lond)       Date:  2012-01-31       Impact factor: 5.095

10.  Longitudinal Weight Change During CKD Progression and Its Association With Subsequent Mortality.

Authors:  Elaine Ku; Joel D Kopple; Kirsten L Johansen; Charles E McCulloch; Alan S Go; Dawei Xie; Feng Lin; L Lee Hamm; Jiang He; John W Kusek; Sankar D Navaneethan; Ana C Ricardo; Hernan Rincon-Choles; Miroslaw Smogorzewski; Chi-Yuan Hsu
Journal:  Am J Kidney Dis       Date:  2017-12-06       Impact factor: 11.072
View more
  1 in total

Review 1.  Primary and Secondary Prevention of Cardiovascular Disease in Patients with Chronic Kidney Disease.

Authors:  Sehrish Ali; Natasha Dave; Salim S Virani; Sankar D Navaneethan
Journal:  Curr Atheroscler Rep       Date:  2019-06-22       Impact factor: 5.113
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.